33.59
-0.49 (-1.45%)
| Penutupan Terdahulu | 34.08 |
| Buka | 33.75 |
| Jumlah Dagangan | 32,554 |
| Purata Dagangan (3B) | 595,958 |
| Modal Pasaran | 1,710,537,728 |
| Harga / Pendapatan (P/E TTM) | 104.95 |
| Harga / Pendapatan (P/E Ke hadapan) | 76.92 |
| Harga / Jualan (P/S) | 6.45 |
| Harga / Buku (P/B) | 4.90 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | 1.25% |
| Margin Operasi (TTM) | -24.32% |
| EPS Cair (TTM) | 0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 2.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 52.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 33.72% |
| Nisbah Semasa (MRQ) | 5.01 |
| Aliran Tunai Operasi (OCF TTM) | 57.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -22.77 M |
| Pulangan Atas Aset (ROA TTM) | -0.45% |
| Pulangan Atas Ekuiti (ROE TTM) | 1.13% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Vericel Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.10 |
|
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.06% |
| % Dimiliki oleh Institusi | 107.99% |
| Julat 52 Minggu | ||
| Median | 64.00 (90.56%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Feb 2026 | 64.00 (90.56%) | Beli | 35.68 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HOPPER JONATHAN MARK | - | 34.14 | -3,472 | -118,534 |
| RUBINO ALAN L | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | -3,472 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -118,534 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 34.14 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HOPPER JONATHAN MARK | Pegawai | 02 Apr 2026 | Jual automatik (-) | 3,472 | 34.14 | 118,534 |
| HOPPER JONATHAN MARK | Pegawai | 02 Apr 2026 | Pelaksanaan pilihan | 3,472 | - | - |
| RUBINO ALAN L | Pengarah | 25 Mar 2026 | Pelaksanaan pilihan | 15,000 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2026 | Pengumuman | Vericel Announces Preliminary 2025 Financial Results and Business Updates |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |